TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Browse trials for

• Renal Insufficiency 1,995
• Kidney Failure, Chronic 2,085
• Renal Insufficiency, Chronic 3,144

Keywords

• ESRD
• Chronic Renal Failure
• Prostaglandin
• Prostacyclin
• Asian Multinational Study

Renal Insufficiency

1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.

This study's enrollment of 892 is above the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.

Lead sponsor

Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Study arms

• Experimental
  TRK-100STP

  Drug: TRK-100STP high dose · Drug: TRK-100STP low dose

• Placebo comparator
  Placebo

  Drug: Placebo

Interventions

• DrugTRK-100STP high dose
• DrugTRK-100STP low dose
• DrugPlacebo

Primary outcomes

1. Renal composite endpoints [Time to first occurrence of one of the following events:]

   (i) Doubling of SCr: Doubling of SCr is defined as a two-fold or greater increase in the SCr level, as compared with the baseline value (ii) ESRD (Occurrence of any of i-iii) i) Introduction of dialysis ii) Renal transplantation iii) Increase in SCr to 6.0 mg/dL or higher

   Time frame: 2-4 year

Publications

• Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. PubMed 35224730 ↗
• Nakamoto H, Fujita T, Origasa H, Isono M, Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S. A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrol. 2014 Sep 19;15:153. doi: 10.1186/1471-2369-15-153. PubMed 25233856 ↗